Example: confidence
Pharmacovigilance Risk Assessment Committee …
Pharmacovigilance Risk Assessment Committee (PRAC) EMA/PRAC/443961/2015 Page 2/94 Table of contents 1. Introduction 12 1.1. Welcome and declarations of interest of members, alternates and experts ..... 12
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Related documents
The evoluTion of Pharmacovigilance - Pugatch …
www.pugatch-consilium.comThe Evolution of Pharmacovigilance 5 r&d Research and Development rld Reference Listed Drug rmP Risk Management Plan SPc Summary of Product Characteristics
WHO Drug Information
apps.who.intMedicines regulation WHO Drug Information Vol. 31, No. 2, 2017 154 within a risk framework that takes into account product and process risks and
NIHS 医薬品安全性情報 Vol.16 No.022018/01/25
www.nihs.go.jp1 . 目 次 各国規制機関情報 【 EU EMA（European Medicines Agency ）】 • シグナルに関するPRAC の勧告―2017 年9 月25～29 日のPRAC 会議での採択分.....2
WHO Drug Information
www.who.int573 WHO Drug Information Vol. 31, No. 4, 2017 Contents Safety of medicines 575 Priming resource-limited countries for pharmacovigilance Naming of medicines 581 Survey about International
WHO Drug Information
www.who.intPre-publication draft - page numbers are not for citation purposes 3 WHO Drug Information Vol. 30, No. 1, 2016 Concept paper for comment A framework for risk-based identificationof essential
Brexit and the impact on patient access to …
www.nhsconfed.orgJanuary 2018 Brexit and the impact on patient access to medicines and medical technologies 03 What is at risk if no solution for medicines and medical devices is …
Overview of the new process for Signal Detection …
www.ema.europa.euAn agency of the European Union Overview of the new process for Signal Detection and Management PCWP and HCPWP joint meeting 25 February 2014